Bullous skin diseases represent a group of organ-specific autoimmune disorders characterised by binding of circulating autoantibodies to adhesion molecules of the epidermis and the dermo-epidermal basement membrane zone. Binding of these autoantibodies to their antigenic targets results in loss of adhesion between epidermal keratinocytes and at the level of the basement membrane zone. Chronic blisters and secondary painful erosions are the clinical hallmark of autoimmune bullous disorders. Histopathology reveals the location of blister formation and helps to classify the subtype of the bullous skin disorder. Immunofluorescence is crucial for diagnosing autoimmune bullous skin disorders. Tissue-bound autoantibodies are detected by direct immunofluorescence of perilesional skin. Circulating autoantibodies can be visualised by indirect immunofluorescence using tissue substrates such as monkey oesophagus and sodium chloride-split human skin. Most of the autoantigens are available as recombinant proteins, which allows for autoantibody screening by ELISA or immunoblot analysis to confirm the primary diagnosis and, importantly, for immunoserological follow-up of patients.
Introduction
Bullous autoimmune skin disorders, including some life-threatening diseases, are manifest in the skin and mucous membranes and are clinically characterised by the appearance of blisters and secondary erosions. Bullous autoimmune dermatoses have a common pathogenic mechanism involving binding of autoantibodies to specific adhesion molecules in epidermal desmosomes, and in some cases in the area of the dermo-epidermal basement membrane zone. The binding of circulating autoantibodies and the induction of an inflammatory reaction in the area of target structures lead to loss of adhesion with subsequent intra-or subepidermal blister formation (1) . The clinical appearance is heterogeneous and secondary eruptions such as erosions, encrustation, impetiginisation, and scarred secondary erosions can dominate the clinical picture. Diagnosis of this organ-specific chronic autoimmune disease is frequently a problem. Therefore, a diagnostic concept to allow standardisation of the available examination methods ( Figure  1 ) was developed by the autoimmune diagnostic working group of the United German Society for Clinical Chemistry and Laboratory Medicine (DGKL).
History and clinical findings
For the most part, bullous autoimmune dermatoses exhibit a chronic progression, in which the principal clinical symptoms are blisters and painful secondary erosions on the skin and mucous membranes that lack a tendency to heal. The most frequent adult bullous skin disease, the bullous pemphigoid (BP), demonstrates taut blisters on the torso and extremities. A prodromal phase with pruritus and papulovesicular or urticarial plaques can precede the occurrence of blisters. In diseases of the pemphigus group, loose fragile blisters are often no longer detectable and erosions with a crusty surface are frequently prominent. Table  1 shows the clinical characteristics of different bullous autoimmune dermatoses.
Clinical differential diagnosis
The most important differential diagnoses of bullous autoimmune dermatoses include: a) infectious diseases in connection with bacterial and viral infections; b) immunological causes, such as bullous druginduced skin rashes or erythema exsudativum multiforme (EEM); and c) the group of hereditary blister-forming dermatoses. Table 2 summarises these differential diagnoses.
Classification of bullous autoimmune dermatoses
Classification of the blister-forming autoimmune skin diseases is based on the localisation of the blister formation (2). The diseases are categorised into three groups: those that exhibit an intra-epidermal loss of Dermatitis herpetiformis Duhring adhesion (acantholysis); those with skin-splitting in the area of the basement membrane zone; and dermatoses with damaged sublaminal adherence. An overview of this classification is given in Table 3 . In diagnosing bullous autoimmune skin diseases, histological examination of diseased skin allows differentiation between intra-and subepidermal blister formation. Thus, histology plays a major role in differentiating intra-epidermal (desmosomal) from subepidermal loss of adhesion. However, definitive classification is not possible from histological findings alone.
Direct and indirect immunofluorescence
Direct immunofluorescence The diagnosis of bullous autoimmune skin diseases involves immunohistological and immunoserological tests (3). Using direct immunofluorescence (DIF) of perilesional skin tissue-bound autoantibodies, mostly classified as IgG, but also including IgA (linear IgA dermatosis, IgA pemphigus, IgA-type Epidermolysis bullosa acqusita), as well as the complement factor C3, can be verified. The localisation of tissue-bound autoantibodies leads to characteristic fluorescent patterns, which allow allocation to specific entities ( Figure 2 ). Intercellular reticulate (desmosomal) deposits of IgG (or IgA in IgA pemphigus) and complement factors (frequently C3) are obvious in all pemphigus diseases. Linear deposits of IgG and C3 in the area of the dermo-epidermal basement membrane zone can be found in the pemphigoid group and Epidermolysis bullosa acqusita. Linear deposits of IgA at the basal membrane are characteristic of linear IgA dermatosis and are also found in IgA-type Epidermolysis bullosa acqusita. The DIF of Dermatitis herpetiformis Duhring shows granular IgA deposits in the dermal papillae and occasionally in the basement membrane area. Figure 3A, B) . In this test, monkey oesophagus is used as a substrate for pemphigus diseases. In certain cases, plakin-rich tissue, such as guinea pig oesophagus or rat bladder epithelia, is used. The different DIF and IIF tests with their respective target antigens are summarised in Table 4 .
Indirect immunofluorescence Indirect immunofluorescence (IIF) detects circulating serum autoantibodies in patients (
An additional substrate for IIF is sodium chloridesplit skin. This test is used to further differentiate pemphigoid, linear IgA dermatosis, and EBA ( Figure  3C -E). Pemphigoid disease and EBA demonstrate immunohistologically linear deposits of IgG and C3 in the area of the dermo-epidermal basement membrane zone. In addition, linear IgA deposits in the area of the basement membrane zone are characteristic of linear IgA dermatosis, but can also be found in the IgA variant of EBA. For the sodium chloride split-skin test, human skin is incubated in 1 M NaCl solution, so that an artificial split is induced in the area of the lamina lucida of the basement membrane zone. This splitting separates pemphigoid autoantigens from those of EBA. Sera of pemphigoid patients typically show IgG binding to target antigens in the area of the blister roof (epidermal part), whereas sera of patients with EBA show IgG reactivity at the base of the blister (dermal part). IgA autoantibodies can be verified in 60-70% of patients with linear IgA dermatosis, with a reactivity to autoantigens in the epidermal area of the NaCl-split skin. A specific characteristic of sera from patients with mucous membrane pemphigoid is that laminin-5 (epiligrin)-reactive sera show reactivity to the epidermal and dermal parts of the NaCl-split skin, where the IgG reactivity shows a typical pattern at the blister base.
Immunoserological tests with recombinant autoantigens or autoantigen extracts
ELISA and immunoblot tests with recombinant and purified native autoantigens are an important addition to the diagnosis of bullous autoimmune dermatoses. The identification of autoantigens of most autoimmune blistering skin diseases has allowed their use in immunoserological procedures in the last few years (4) (5) (6) (7) (8) . These antigens are either prepared by recombination or from epidermal extracts or cultured keratinocytes. Commercial test systems are currently only available for the autoantigens Dsg1/Dsg3 (pemphigus group) for the NC16A region of BP (bullous pemphigoid) and for tissue transglutaminase (dermatitis herpetiformis). A type VII-collagen has been described for EBA, but is not commercially available (9) . Therefore, dermal protein extracts for immunoblot analysis are used for proof of autoantibodies in EBA. Furthermore, specialised laboratories, including the Departments of Dermatology in Marburg, Freiburg, and Lü beck, carry out additional serological tests in the form of ELISAs, immunoblots, and immunoprecipitation with recombinant and native varieties of the autoantigens Dsg1/Dsg3, BP180/BP230 and laminin-5 (10) (11) (12) .
Diagnostic course
The current immunoserologic course of tests commonly used is based on recent developments in the diagnostic field of bullous autoimmune skin diseases. ELISA tests are at present the most important method for diagnosis. A correlation between disease activity and antibody titres was verified, especially for pemphigus and pemphigoid diseases (13) . The frequency of serological controls during the disease course mainly depends on the clinical picture. In phases of active disease, monitoring of autoantibodies is recommended every 4 weeks. With stable skin conditions, quarterly check-ups seem reasonable.
Fundamentally there are three goals. In the first instance, ELISA tests, as well as semi-quantitative immunoblots and immunoprecipitation, allow a correlation between the clinical picture and the extent of the antibody titre. Secondly, these examination methods allow characterisation of the autoantibody subclasses. In the acute stages of pemphigus disease there is already evidence that besides IgG 4 , desmoglein-reactive autoantibodies of the class IgG 1 can be detected, as well as sporadic detection of IgE (7) . Thirdly, characterisation of the epitope specificity of autoantibodies is possible (14, 15) . Therefore, immunoserology not only confirms diagnosis, but also provides a better understanding of the immunopathogenesis of these diseases.
